J. smoid Biochem.
`
`32, No.
`
`21-25, 1989
`
`0022-473 l/89 $3.00 + 0.00 Printed in Great Britain. All rights reserved Copyright 0 1989 Pergamoo Press plc PHARMACOKINETICS OF THE ANTIPROGESTERONE RU 486 IN WOMEN DURING MULTIPLE DOSE ADMINISTRATION OSKARI HEIKINHEIMO* Steroid Research Laboratory, Department of Medical Chemistry, University of Helsinki, Helsinki, Finland
`
`(Received 31 October 1987; receiued for publication 4 July 1988)
`
`486
`
`RU
`
`Summary-Serum levels of RU 486 were measured by high performance liquid chromatography (HPLC) following oral intake of 12.5, 25, 50 and 100 mg twice daily (b.i.d.) for 4 days, 50 mg b.i.d. for 7 days, as well as a single dose of 200 mg of RU 486. The pha~aeokinetics of RU 486 were not linear: when the daily dose of RU 486 was 100 mg or more, the serum levels were similar. The pharmacokinetic behaviour of RU 486 during the treatment period was similar between the study subjects, whereas the elimination phase pharmacokinetics showed wide individual variation. Also the mean elimination phase half-lifes (ti,r) of RU 486 varied from 25.5 to 47.8 h in the groups of different regimen, yet the variation between different groups was not statistically significant. The areas under the concentration curves (AUC) were calculated. In the multiple dose study (mds) the AUC,,,,,,: s decreased when the administered dose of RU 486 was increased. The AUCe+t2h seen after a~inistration of 100 mg b.i.d. x 4d. (mean + SEM = 0.43 rf: 0.04 pmoljl x h/mg) was signilicantly (P < 0.05) lower than the AUC,,,,,: s obtained with administration of 12.5 mg b.i.d.x4d.(1.49f0.37~mol/lxh/mg),25mgb.i.d,x4d.(1.09~0.15~mol/lxh/mg),and50mg b.i.d. x 7d. (0.72 k 0.11 pmol/l x h/mg). The AUC e._ obtained by administration of a single dose of 200 mg of RU 486. (sds) was 0.67 k 0.21 pmol/l x h/mg. It is concluded that if multiple dose administration of RU 486 is preferred, daily administration of relatively small doses of RU 486 over several days seem to be advantageous. INTRODUCTION In attempts to terminate early human pregnancy, various regimens of the antiprogesterone RU 486 have been used. In the studies published so far, the overall success rate with treatment periods of 2-7 days, and daily doses of RU 486 ranging from 50 to 400 mg, has varied from 60 to 85% [l-6]. However, no clear dose-response correlation with clinical per- formance has been found [IA]. Preliminary reports suggest that in very early pregnancy a large single dose of RU 486 (i.e. 600 mg) is clinically as effective as multiple dose administration of the compound [7]. Our earlier work on the initial pharmacokinetics of RU 486 following single oral doses ranging from 100 to 800 mg revealed that serum levels of RU 486 were generally not significantly different; partly because of saturation of the serum binding capacity for RU 486, and effective metabolism of the compound [S]. Serum levels of demethylated and hydroxylated metabolites of RU 486 increased along with the increased dose following single oral administration of RU 486 to female volunteers 181. Hence, to study the pharma- cokinetics of RU 486 in women during multiple dose *Address for correspondence: Steroid Research Laboratory, Department of Medical Chemistry, University of Helsinki, Siltavuorenpenger 10 A, SF-00170 Helsinki, Finland. Presented in part at the
`Copenhagen, Denmark, 1987. administration of the compound, serum levels of
`following various regimens were examined. EXPERIMENTAL RU 486 (17@-hydroxy-I 1~~(4-dimethylamino- phenyl)-l7a-(propynyl)-estra~,9-dien-3-one) tablets (5, 10 and 50mg), [6,7-‘H]RU 486 and the corre- sponding antibody were kindly donated by Roussel- Uclaf Research Center (Romainville, France). Healthy normally menstruating female volunteers, aged 22-40 yr and weighing 4670 kg, participated in the study.
`Groups ingesting 12.5, 25, 50 and 1OOmg of RU 486 twice daily (b.i.d.) for 4 days, and 50 mg b.i.d. for 7 days, each consisted of six volunteers. Thus the total doses of RU 486 were 100, 200, 400, 800 and 700mg, respectively. Volunteers were advised to in- gest RU 486 at 9.00-10.00 and at 21.00-22.00h, beginning on day 12 of the luteal phase (day 0) of the cycle during an hCG-induced pseudopregnancy [for details, see ref. 91. Blood samples were collected daily at 9.00 h prior to ingestion of RU 486. In the groups ingesting RU 486 for 4 days or 7 days, serum samples were collected daily up to day 5 or day 7, respectively. Figure 1 depicts the protocol of RU 486 adminis- tration and sample collection. Some samples were also collected at 9.00 h during the 12 days following the end of RU 486 administration. 21
`
`Multiple dose study (mak)
`
`crinology,
`
`First European Congress of Endo-
`
`1
`
`TEVA1016
`
`Vol.
`iA, pp.
`

`

`OSKARI HEIKINHEIM~
`
`DAY
`RU 486
`
`SAMPLES
`
`Fig. I. The protocol of RU 486 administration and col- lection of serum samples in the multiple dose study. Single dose stm+ (sds) The group ingesting a single dose of 200 mg of RU 486 in the mid-luteal phase of the cycle (6-8 days after the LH-surge) consisted of 4 female volunteers. Blood samples were collected at - l/2, 0, 1, 2, 4, 6 and 10 h; thereafter daily up to 7 days and on days IO and 14. Serum levels of RU 486 were measured using Chromosorb”-column chromatography prior to quantitation by high performance liquid chro- matography (HPLC) [lo]. In these HPLC-studies the intra- and interassay coefficients of variation were 4.9 and I IS%, respectively. In mds the concentrations of RU 486 measured on days 14 and l-7 following 4 and 7-day treatments, respectively, are referred to as C,,,. The normalized areas under the serum concentration curves (AUC,..,,, ,,) were calculated over one dosage interval by trapezoidal rule using the C,,,: s measured on days 3 and 4, and thereafter divided by the corresponding dose. In sds the AUC, ,1 was calculated by the trapezoidal rule, and thereafter divided by the dose. In mds the half-lifes (t,:2) were calculated from the concentrations of RU 486 measured following termi- nation of RU 486 administratiotl, and in sds from the concentrations of RU 486 measured after 24 h. One-way analysis of variance (ANOVA) was used to assess the difference
`Figure 2 shows the serum concentrations of RU 486 (mean + SEM) following oral administration of 12.5, 25, 50 and 100mg of RU 486 b.i.d. for 4 days. 01 1 4 10 15 day?. Fig. 2. Serum levels of RU 486 (mean + SEM) following ingestion of 12.5, 25, 50 and 100 mg of RU 486 b.i.d. for 4 days. In all groups the highest mean Cm,“: s were measured on day 3, and they were 1.7, 2.6, 3.6 and 3.8pmol/l in the groups receiving 12.525, 50 and 100 mg of RU 486 b.i.d., respectively. For the first 2 days of the RU 486 treatment, the C,,, : s were at the same level in the groups ingesting 25, 50 or 100 mg of RU 486 b.i.d. Throughout the study, the C,;, of RU 486 seen after the dose of 12.5 mg b.i.d. were approximately half of those seen after the higher doses of 50 and 100 mg b.i.d. (Table I). The individual (open symbols) and the mean + SEM (solid circles) serum concentrations of RU 486 following 7-day administration of 50mg of RU 486 b.i.d. are depicted in Fig. 3. Serum levels were similar to those seen after the 4-day treatment. The highest mean C,,, of RU 486 (3.3 pmol/l) was measured on day 3. The mean concentrations were measured to remain above 2.2 pmol/l throughout the 7-day tre;itment period, and thereafter they began to decline. During the treatment period the individual C,,,:s of RU 486 were similar in all six volunteers. However, the elimination phase pha~a~k~netics showed a wide range of variation. The t,:, of RU 486 in these patients was 40.9 & 6.2 h (mean f SEM) (Table 2). In volunteer No. 1, RU 486 was detectable in serum up to 12 days following termination of the RU 486 administration. In the samples collected following administration
`
`in
`
`AUC and tt,‘2 between the groups of different regimen. The AUC:s obtained by various regimens were thereafter compared using the Welch two-tailed t-test. In mds the effect of time and regimen of RU 486 on C,, : s measured on days 1-4 were evaluated using two-way ANOVA. The AN- 0VA:s were performed with the StatWorks- statistical software (Cricket Software, Inc., Philadel- phia. PA, U.S.A.).
`
`RESULTS
`
`of RU 486 [mean + SEM, (n)] following
`Table I. Serum
`(A). 25 me (B). 501~ CC) and lOOme (D) b.i.d. for 4 days and 50ma b.i.d. for 7 days (E)
`
`DW
`
`A
`
`B
`
`C
`
`D
`
`E
`
`2.
`3.
`4.
`5.
`
`7.
`
`I .5 t 0.4 (5)
`I.7 * 0.4 (6)
`1.7 + 0.5 (6)
`1.4 i 0.5 (6)
`1.0 f 0.2 (4)
`0.4 f 0.3 (3)
`0.5 + 0.1 (3)
`
`2.6 + 0.6 (5)
`2.5 -?r: 0.4 (5)
`2.6 zt 0.3 (6)
`2.0 + 0.4 (6)
`t .6 * 0.3 (4)
`
`0.4 It: 0.
`
`(5)
`
`(6)
`3.1 IO.9
`3.5 i 0.8 (6)
`3.6 + 1.4 (5)
`2.9 i 0.4 (5)
`2.2 & 0.2 (5)
`1.2 i 0.1 (3)
`0.6 i 0.2 (3)
`
`2.3 & 0.5 (6)
`2.8 f 0.5 (6)
`3.9 + 0.4 (6)
`3.3 i: 0.4 (6)
`2.5 + 0.4 (3)
`
`+ 0.5 (3)
`
`1.8 + 0.3 (6)
`2.5 + 0.3 (6)
`3.3 t 0.6 (5)
`3.0 i 0.4 (6)
`3.0 t 0.3 (5)
`2.6 + 0.4 (5)
`2.3 + 0.3 (3)
`
`2
`
`22
`concentrations (~mol/l)
`ingestior? of 12.5 mg
`1.
`6.
`I
`I.4
`

`

`P
`
`P <
`
`cor-
`
`Pharmacokinetics of RU 486 23 -fable 2. AUC,,_rlzh. -s and 1,,2: s [mean f SEM, (n)] following inges- tion of 12.5.25, 50 and 100 mg b.i.d. for 4 days and 5Omg b.i.d. for 7 days. Also AUC&., and f,,* following ingestion of a single dose of 200 mg is included. AUC q;z Regimen fCrmol/l x bims) (hours) 12.5mg b.i.d. x 4d 1.49 k 0.37 (6) 29.5 k 3.6 (5) 2S.Omg b.i.d. x 4d 1X9+0.15 (6) 25.5 f 1.4 (6) SO.Omg b.i.d. x 4d 0.78 + 0.21 (5) 31.8 + 4.0 (6) iOO.Omg b.i.d. x 4d 0.43 k 0.04 (6) 47.8 f 7.8 (6) 50.0 mg b.i.d. x 7d 0.72 * 0. I 1 (5) 40.9 f 6.2 (5) 200 mg single dose 0.47 & 0.2t (4) 29.1 +_ 8.3 (4) ANOVA f 3.167 1.922 df 5.26 6,24
`0.025 ns. of 50mg of RU 486 b.i.d. for 7 days, the concen- trations of RU 486 were also measured by RIA following the Chromosorb%-column chromato- graphy as described earlier [lo]. There was a good correlation between the serum levels of RU 486 measured by HPLC and RIA (Fig. 4). The
`relation coefficient was 0.92 (n = 80), but at the serum ~on~ntratio~s exceeding 0.64 pmol/l RIA gave higher values than HPLC. The equation for the linear regression line was HPLC = 0.55 RIA + 0.29 pmol/l. Figure 5 depicts the mean concentrations (+ SEM) of RU 486 in four women after single oral intake of 200 mg of RU 486. The peak levels of RU 486 (mean + SEM = 4.9 f 1.2 pmol/l) were measured at 1 h after ingestion. After the initial redistribution period within 6 h, a plateau was reached until 24 h. The mean ( & SEM) concentration of RU 486 at 1, 2 and 3 days were 1.8 rl: 0.4, 1.1 f 0.3 and 0.6 + 0.3 pmol/l, respectively. The lljz of RU 486 in these subjects was 29.1 4 8.3 h (mean _t SEM, Table 2). The serum concentrations of RU 486 measured for the first 7 days in the mds are displayed in Table 1. In all groups of different regimen the highest mean C&,: s were measured 3 days after beginning of the RU 486 treatment. Two-way ANQVA did not indi- cate statistically significant effect of time on Cmin:s measured on days 14 in the groups of different regimen (ANOVA
`
`The mean t,,*+ *s showed a wide range of variation between the groups of different RU 486 regimen, however one-way ANOVA did not indicate statisti- S.B 32/IA< tally significant variation between the fllz: s measured in the different groups. DE%3JSSION Various oral doses of RU 486 have been used in clinical work. Large doses of 2 400 mg of RU 486 are required for clinical antiglucocorticoid effects [ 11, 121, whereas the optimal regimen of RU 486 for anti- progesterone action remains obscure [l-4]. Daily doses of 50 mg or more of RU 486 have been used in previous clinical studies in order to terminate early human pregnancy [l-6]. With two different regimens of RU 486, i.e. 25 mg and 50 mg b.i.d. for 7 days, Odlind and Birgerson reported equal success rates of 61% 141. Using more strict patient selection and three different regimens of RU 486, namely 50 mg b.i.d. for 4 days, 50mg 3 times daily for 4 days, and 400mg daily for 2 days, Couzinet et al. were able to terminate early pregnancy equally in 82, 88 and 85% of their patients, respectively [3]. Success rates of 60 and 72% reported by Cameron et al. and by Shoupe et af. following ingestion of 150 mg daily for 4 days and 100 mg daily for 7 days, respectively, are in the same range as the other clinical data published so far [5,6]. Recent reports suggest that administration of RU 486 at daily doses of 25 and 50 mg might be on the threshold of being effective for induction of uterine bleeding or for te~ination of early pregnancy, re- spectively [Ii. Croxatto, pers. commun., 131. In previously published clinical articles, the serum levels of RU 486 have been measured by direct RIA [3, 14,151, which also measures some of the matabo- lites of RU 486 1141. The lower precision and accu- racy of RIA at high concentrations of RU 486 [IO] could explain the higher values obtained by this method (Fig. 4). Due to its higher accuracy at high serum levels of RU 486, the specific HPLC method was chosen for the present study. ?I. 0-Q 3 2.5. 1.0. *. #*5- ‘:. b Fig. 3. The individual (open symbols) and mean + SEM (closed circles) serum concentrations of RU 486 following intake of SOmg b.i.d. for 7 days. the f,12 of RU 486 (mean f SEM) in these volunteers was 40.9 f 6.2 h.
`
`f =
`
`P = 0.182).
`
`Table 2 shows the AUC : s and r,,2: s of RU 486 in all the groups of different regimen studied. One-way ANOVA revealed statistically significant variation in the ALJC: s (P < 0.025) calculated for the different groups. In the mds the AUC,,,,,:s decreased when the administered dose of RU 486 was increased, the smallest AUC,_,,2 h was obtained with the regimen of 100 mg b.i.d. for 4 days. The AUCO_+lzL: s following ingestion of 12.5 mg
`
`(P <
`(P <
`(P ~0.05) were
`0.005) b.i.d. x 4d, and 50mg b.i.d. x 7d
`
`statistically significantly different when compared by the Welch two-tailed r-test to the AUCO_IZL follow- ing ingestion of 100mg of RU 486 b.i.d.
`
`x 4d.
`
`3
`
`1.660, df = 3,113,
`0.05), 25.0 mg
`

`

`24
`
`151.
`
`OSKARI HEIKINHEIMO 1 , 0 2.5 30 25 10.0 *lo RIA -“qQL Fig. 4. Comparison of HPLC and RIA after Chromosorba-column chromatography in the assay of RU 486 in serum. Serum samples were collected following oral intake of 50.0 mg b.i.d. for 7 days. The equation for the linear regression line was HPLC = 0.55 RIA + 0.29 pmol/l, and the correlation coefficient was 0.92 (n = 80). Previous work on the pharmacokinetics of RU 486 has shown that by increasing a single oral dose from 100 to 800 mg, the serum levels of RU 486 cannot be greatly elevated [8]. A similar phenomenon has also been reported to occur during multiple dose adminis- tration of the compound [ 161. The equal C,i, : s of RU 486 during the treatment period following intake of daily doses exceeding 50 mg (Table 1) is at least partly explained by saturation of alpha l-acid glycoprotein, the specific transport protein of RU 486 18, 171. The serum concentrations of the mono- demethylated, didemethylated and hydroxylated me- tabolites of RU 486 increased significantly when the single oral dose of RU 486 was increased from 100 to 800 mg; thus equalling or exceeding the serum levels of the parent RU 486 [8]. These metabolites bear lower affinities of 9-21% (RU 486 = 100%) to the human progesterone receptor [18]. Even though the monodemethylated and hydroxylated metabolites behave as weak antiprogesterones in rat [19], the antiprogestagenic nature of the metabolites of RU 486 in humans has not been confirmed. Thus. from Fig. 5. Serum concentrations of RU 486 in four female volunteers (mean + SEM) following oral intake of a single dose of 200 mg of RU 486. the pharmacokinetic point of view, the optimal dos- age could be the one leading to the highest serum and target tissue levels of RU 486: the strongest com- petitor for the progesterone receptor and the best characterized antiprogesterone of these steroids. In agreement with previous pharmacokinetic data [ 10, 16],4 and 7-day treatment with daily doses of 100 and 200mg of RU 486 resulted in nearly identical &:s of RU 486 during the treatment period (Figs 2 and 3, Table 1). In the mds the AUC,,,,,: s decreased when the administered dose of RU 486 was increased (Table 2). The AUC,,,,, seen after admin- istration of 100 mg b.i.d. for 4 days was significantly lower than the AUC O_lZh:~ obtained with adminis- tration of 12.5mg b.i.d. (P < 0.05) 25 mg b.i.d. (P < 0.005) for 4 days, and 50 mg b.i.d. (P < 0.05) for 7 days. This may further suggest that if multiple dose administration of RU 486 is preferred, daily administration of relatively small (i.e. around 5SlOOmg/day) single doses of RU 486 might be advantageous. This might also decrease possible side- effects of RU 486 associated with high oral doses [6,
`The elimination phase pharmacokinetics of RU 486 showed a wide range of individual variation (Fig. 3) suggesting large individual variation in the capacity to metabolize and excrete RU 486. The mean t,;,:s of RU 486 varied from 25.5 to 47.8 h in the groups of different regimens (Table 2) however the variation was not statistically significant. A large single dose of RU 486 (i.e. 600mg) has been reported to be clinically equally effective as multiple dose administration in very early pregnancy [7]. The AUC,,, following intake of a single dose of 200mg of RU 486 was in the same range with the AUC ,,_,1 h: s seen in mds (Table 2) indicating that single dose administration of RU 486 may be as efficient as multiple dose administration. Also, due to the long tlj2 of RU 486 [Table 2, refs 10, 191, single dose administration might lead to sufficiently high and prolonged serum levels of RU 486 to ensure saturation of the progesterone receptors. In addition, in order to avoid possible misuse of RU 486 [3], single dose administration of the compound would be pref- erable. On the other hand, the clinical potency of the single dose administration of RU 486 declined from 89% in pregnancies of less than 5 weeks amenorrhoea to 58% when the duration of pregnancy exceeded 6 weeks [7]. Therefore multiple dose administrations of RU 486 might be needed in more advanced preg- nancies. Previously, with daily doses of 50 mg or above, the abortifacient properties of RU 486 have been re- ported to lack dose-dependency [l-6]. Following multiple daily administration of 100mg or more of RU 486, the C,,,: s were similar during the treatment period (Table 1). This phenomenon is partly due to saturation of the specific serum transport capacity for RU 486, and effective metabolism of the compound [8]. Therefore, due to saturation of the serum binding
`
`4
`
`

`

`Pharmacokinetics of RU 486 25 capacity for RU 486 [Fig. 2, ref. 81, the quantitation of RU 486 in serum following intake of doses exceed- ing SOmg may not be very informative. It is con- cluded that from the pha~acokinetic point of view, administration of RU 486 as relatively smail daily dose administered over several days seem to be advantageous. ~cknowiedgeme~~s-I wish to thank Drs Maija Haukka- maa, Donna Shoune, Horatio Croxatto, Kari KivistG. Pekka L$ihteenm&ki Tapani Luukkainen and Juhani Toi: vonen for their help and constructive criticism of this manuscript. MFS Tuula Kivi and Mrs Mariatta Tevilin are to be thanked for their expert technical heip. The financial support provided by the Suomalainen Lit~klriseura Duo- decim, the Ford Foundation and the Mello Foundation is gratefully acknowledged. The content does not necessarily reflect the policy of any of the funding sources. REFERENCES t3. 1. Kovacs L., Sas M., Resch 3. A., Ugocsai G., Swahn M, L., Bygdeman M. and Rowe P. J.: Te~ination of very early pregnancy of RU 486--an antipro~~tional compound. Con~~uce~r~~~ 29 (1984) 399-410. 2. Vervest H, A. M. and Haspels A. A.: Preliminary results with the antiprogesta~onal compound RU-486 (mi- fepristone) for interruption of early pregnancy. Fert. Sferil. 44 (1985) 627-632. 14. 15. 3. Couzinet B., Le Strat N., Ulmann A., Baulieu E. E. and Schaison G.: Termination af early pregnancy by the progesterone antagonist RU 486 (mifepristone). N. &rg!. J. Med. 315 (1986) 1565-1569. 4. Biqerson L, and Odhnd V.: Early pregnancy termi- nation with antiprogestins: a comparative clinical study of RU 486 given in two dose regimens and Epostane, Fert. Sterit. 48 (1987) 565-570. 16. 5. Cameron I. T., Michie A. F. and Baird D. T.: Ther- 17. apeutic abortion in early pregnancy with anti- progestogen RU 486 alone or in combination with prostaglandin analogue (Gemeprost). Corttracep$ion 34 (I986) 459-468. Shoupe D., Mishell D. R. Jr, Brenner P. F. and Spitz I. M.: Pregnancy termination with a high and medium dosage regimen of RU 486. Contraception 33 (1986) 455-461. Elia D.: Uses of RU 486: a clinical update. ZPPF Med. B&f, u) (1986) 1-2. ~eikin~eimo O., ~h~~~ki P. L. A., Koivnnen E., Shoupe D., Croxatto H., Luukkainen T. and LIih- teenmlki P.: Metabolism and serum binding of RU 486 in women after various single doses. Human Reprod. 2 (1987) 379-385. 9. IO. If. 12. Croxatto H. IL, Spitz I. M., Salvatierra A. M. and Bardin W. C.: The demonstration of the antiprogestin effects of RU 486 when administered to the human during hCG-induced pseudopregnancy. In The Anti- ~oge~~~ Steroid RU 486 mrd Humon ~e~i~~~~ Conrrol (Edited by E. E. Baulieu and S. J. Segal). Plenum Press+ New York (1985) pp. 263-269. Heikinheimo O., Tevilin M., Shoupe D., Croxatto H. and ~ht~nrn~ki P.: ~antitatjon of RU 486 in ham plasma by HPLC and RIA after column chro- matography. Co~Ir~ce~r~o~ 34 (1986) 613-624. Etertagna X.. Bertaana C.. Luton J.-P.. Husson J.-M. and &ard F.: Theiew steroid analog RU 486 inhibits ghtcocorticoid action in man. J. clin. Endocr. Metab. 59 (1984) 25-28. Nieman L. K., Chrousos G. P., Kellner C., Spitz I. M,, Nisula B. C., Cutler G. B., Merriam G. R., Bardin C. W. and Loriaux D. L.: Successful treatment of Cush- ing’s syndrome with the glucocorticoid antagonist RU 486. 3. cl&, Endocr. Metub. 61 (1985) 536-540. M&hell D. R. Jr, Shoupe D., Brenner B. F., Lacarra M,, Horenstein J,, Lghteenmgki P. and Spitz 1.: Termi- nation of early gestation with the anti-prog~ti~ steroid RU 486: medium versus low dose. Contraception 35 (1987) 307-321. Salmon J. and Mouren M.: Radioimmunoassay of RU 486. In The ~~~i~roges~jn Steroid RiJ 486 and !&man Fervidity Controi‘(Edited by E. E. Bauheu and S. J. Seaall. Plenum Press. New York (19851 DD. 99-101. BeTtagna X., Bertagna C., La&at M--H., Husson J.-M., Girard F. and Luton J.-P.: Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing’s syndrome. J. clin. Endocr. hfetab. 63 (1986) 639642. Swahn M, L., Wang G., Aedo A. R., Cekan S. Z. and Eygdeman M.: Plasma leveis of antiprogestin RU 486 following oral administration of non-pregnant and early pregnant women. Conrru~ep~io~ 34 (1986) 469-481. Phili~rt D.. Mo~ilewskv M.. Bonnat C.. Busianv M. and Pottier. J.: I&ence~of human alphi I-a;d’gly- coprotein (AAG) on p~~aco~ne~ and bioiogical activity of- RU 486. Sixty-Eighth Meering
`
`the Endo- crine Society, Anaheim, CA, 1986, Abstract 1006. 18. 19. Heikinheimo O., Kontula K., Croxatto H., Spitz X., Luukkainen T. and Liihteenmiiki P.: Plasma concen- trations and receptor binding of RU 486 and its metab- olites in humans. J. steroid Biochem. 26 (1987) 279-284. Deraedt R,, Bonnat C., Busigny M., Chatelet P., Cousty C., Mouren M., Philibert D.. Pottier J. and Salmon J.: Pha~acokineti~ of RU 486. in The Antiprogestin Steroid RU 486 and Human Ferrifity Control fEdited by E. E. BauIier and S. J. Segaf). Plenum Press, New York (1985) pp. 103-122.
`
`of
`
`5
`
`

`

`IA. JANUARY I989
`THE JOURNAL OF STEROID BIOCHEMISTRY. VOL. 32. NO.
`_______________________._.__—-————-——-—-—
`
`EDITORS-IN~CHIEF
`
`J. R. PASQUALINI and R. SCHOLLER.
`Foundation for Hormone Research.
`26 Boulevard Brune. 75014-Paris. France
`
`H. ADLERCREUTZ. Helsinki, Finland
`M. BEATO. Marburg/Lahn. F.R.G.
`J. CRABBé. Brussels. Belgium
`E. GURPIDE. New York. U.S.A.
`J-A. GUSTAFSSON. Huddinge. Sweden
`E. V. JENSEN. Zurich. Switzerland
`
`ASSOCM TE EDITORS
`A. E. KELLIE. London. England
`M. E. LIPPMAN. Bethesda. MD. U.S.A.
`
`L. MARTINI. Milan. Italy
`A. MUNCK. Hanover. NH. U.S.A.
`B. W. O‘MALLEY. Houston. TX, U.S.A.
`
`D. O. TOFT. Rochester. MN. U.S.A.
`
`CORRESPONDING EDITORS
`A W. NORMAN. Riverside. U.S.A.
`V. HAsssoN. Oslo. Norway
`A. AAKVAAG. Bergen. Norway
`H.
`OKADA. Kyoto. Japan
`K. B. Hottwtrz. Denver. USA,
`S. ANANCHENKO. Moscow. USSR.
`. J. PARKER. London. England
`I. HUHTANIEMI. Turku. Finland
`F. Auntccrtto. Naples. Italy
`.
`PEREZ—PALACIOS. Mexico City. Mexico
`D. R. IDLER. Newfoundland. Canada
`P. L. BALLAIto. San Francisco. U.S.A.
`W. B. PRATI'. Ann Arbor. U.S.A.
`V. H. T. JAMS. London. England
`P. A. BELL. East Hanover. U.S.A.
`J. P. RAYNAUD. Paris. France
`J. KATo. Yamanashi-ken. Japan
`E. W. BERGINK. 055. The Netherlands
`G. Rousseau. Brussels. Belgium
`B. S. KATZENELLENMXBEN. Urbana.
`J. BLAQUIER. Buenos Aires. Argentina
`W. T. SCHRADER. Houston. U.S.A.
`USA.
`R. BOUILLON. Leuvcn. Belgium
`K. SCHUBERT. Jena. G.D.R.
`A. M. KAYE. Rehovot. Israel
`5. Bounceors. San Diego. USA.
`M. SERIO. Florence. Italy
`R. J. 8. KING. London. England
`A. BRODIE. Baltimore. U.S.A.
`J. SiOVALL. Stockholm. Sweden
`F. LAaRIE. Quebec. Canada
`K. J. CAT‘I'. Bethesda. U.S.A.
`A. SPAT. Budapest. Hungary
`C. P. LAN‘I’os. Buenos Aires. Argentina
`L. CEDARD. Paris. France
`L. STARKA. Prague. Czechoslovakia
`5. LIAo. Chicago. U.S.A.
`J. A. CIoLowst. Chapel Hill. U.S.A.
`C. SUMIDA. Paris. France
`P. C. MACDONALD. Dallas. USA.
`J. H. CLARK. Houston. USA.
`J. R. TATA. London. England
`8. S. MCEWEN. New York. U.S.A.
`0. DAXENEICHLER. Innsbruck. Austria
`W. TAYLOR. Tynemouth. England
`W L MrGutRE. San Antonio. U.S.A
`L. Denennm. Fresnes. France
`P. TUOHIMAA. Tampere. Finland
`E. MENINE. Rome. Italy
`E. R. DESOMBRE. Chicago. U.S.A.
`5. Uncut. New York. USA.
`E. MILGROM. Le Kremltn-Bicétre.
`M. L. DUFAU. Bethesda. U.S.A.
`France
`G. VERIIOEVEN. Leuven. Belgium
`H. A. ERIKSON. Stockholm. Sweden
`A. VERMEULEN. Ghent. Belgium
`W R. MILLER. Edinburgh. Scotland
`J. FISHMAN. New York. USA.
`R. Vtrttto. Oulu. Finland
`T Monsoon. Augusta. USA.
`K. FOTIIERBY. London. England
`C. A. VILLEE. Boston. US A.
`J. MULLER. Zurich. Switzerland
`J. W. FUNDER. Melbourne. Australia
`K. D. Voror. Hamburg. F.R.G.
`8. E. P. MURPHY. Montreal. Canada
`G. URI-ENE. Chicago. U.S.A.
`A. E. WAKELING. Macclesfield. England
`M. NEVE-E-CASTRO. Lisbon. Portugal
`K. GRIFFITHS. Cardiff. Wales
`C. R. WIRA. Hanover. U.S.A.
`M. 1. NEW. New York. U.S.A.
`B. GRONER. Bern. Switzerland
`—__________._____.—————-———-—
`Publishing Office
`Journals Production Untt. Pcrgamon Press plc. Hennoclt Road. Marsh Barton. Exeter. Devon EX2 SNE. England
`(Tel. Exeter (0392) 51558; Telex 42749)
`
`M G
`
`Subscription and Adr‘r'rtisr'ng Offices
`North America. Petgamon Press Inc.. Maxwell House. Fairview Park. Elmsl'ord. NY 10523. U.S.A.
`Rest of the World: Pergamon Press plc. Headington Hill Hall. Oxford OX3 08W. England
`(Tel. Oxford {0865} 64881)
`insurance. Annual institutional subscription rote (I939) DM ”35.00:
`including postage and
`Subscription per enntmt (1989).
`l subscription rate for those whose library subscribes at the regular rate
`2-year institutional rate 0989/90) DM 3296.50; persona
`(I989) DM I76. Payments to be made in odz‘anee. Prices are subject to amendment without notice.
`reviously published volumes are available direct from Per amon Press. Back issues
`Mirroforrn Subscriptions and Back Issues: Back Issues of all p
`300 North Zeeb Road. Ann Arbor. MI 43l06. U.
`.A.
`or Pergarnon journals In microl’onn can he obtained from UMI.
`Published [8 issuestannum
`
`Copyright -'t".- 1989 Pergamon Press pie
`submitted
`ublished and will not he simultaneous!
`It is a condition of publication that manuscripts submitted to this journal have not been
`or publishedelsewhere. By submitting a manuscript. the authors agree that the copyright or their article is lransl'erred to the pub isher if and
`when the muck is accepted for uincation. However. assignment of copyright is not required from authors who work for organizations which
`c copyright covers the exclusive rights to reproduce and distribute the article. including reprints. photographic
`do not permit such assignment.
`odueod. stored
`d translations. No part of this publication may be rep:
`reproductions. microfortn or any other reproductions of similar nature an
`electrostatic. magnetic tape. mechanical. photocopying. recording
`In a retrieval system or transmitted in any form or by any means. electronic.
`or otherwise. Without permission in writing from the copyright holder.
`Pint
`Information for men In the USA.
`hotocopy items for internal or personal use is granted by the copyright
`The Item-fee Code for this publication indicates that authorization to p
`'stemd with the Corgsright Gearance Center (CCC) Transactional Reporting Service provided the stated
`holder I'orlibraries and other users
`of the US. Copyright Law. is
`paid. 111: appropriate remittance of $100 per copy
`by Section ID? or
`fee for copying. beyond that pertrtitl
`ter Inc.. 2'? Congress Street. Salem. MA (”970. U.S.A.
`per article is paid directly to the Copyright Clearance Cen
`Paulie-fawn
`The copyright owner's consent does not extend to engaging for general distribution. for promotion. for creating new works or for resale. Specific
`written permission must be obtained from the publts er for such copying.
`The Item-[n Code for this publication is: (1322-4131189 $3.00 + 0.00
`
`6
`
`

`

`the journal of
`
`Volume 32 Number 1A January 1989
`
`
`
`Pergamon Press
`
`Oxford New York Beijing Frankfurt 8&0 Paulo Sydney Tokyo Toronto
`
`7
`
`